While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.
- cystic fibrosis
Hennig, S., Stanning, J., Staatz, C., & Thomson, A. (2013). Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clinical Pharmacokinetics , 52(4), 289-301. https://doi.org/10.1007/s40262-013-0036-y